<< Back To Search

Personalized Autologous Transplant for Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
Scientists are testing a medicine called mephalan to see how much is safe and effective for people with a kind of cancer called multiple myeloma. Mephalan works by stopping cancer cells from growing. They are testing a new way of giving the medicine based on a person's blood levels to find the right dose for each person. This could help doctors give the right amount to each patient to help them get better.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?